期刊
EUROPEAN RADIOLOGY
卷 32, 期 9, 页码 6536-6544出版社
SPRINGER
DOI: 10.1007/s00330-022-08669-8
关键词
Hodgkin lymphoma; Immunotherapy; Immune checkpoint inhibitors; PET; Pseudoprogression indeterminate response
The development of immunotherapy, particularly immune checkpoint inhibitors (ICIs), has greatly improved cancer treatment. This article reviews the use of FDG-PET/CT in patients with Hodgkin lymphoma treated with ICIs, focusing on image interpretation for response monitoring and detecting adverse events.
The development of immunotherapy has revolutionized cancer treatment, improving the outcome and survival of many patients. Immune checkpoint inhibitors (ICIs), the most common form of immunotherapy, use antibodies to restore T-cells' anti-tumor activity. Immune checkpoint inhibitors are gaining ground in the therapeutic strategy across various cancers. Although widely used in solid tumors, ICIs have shown remarkable efficacy in patients with Hodgkin lymphoma. 2-[F-18]Fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET)/CT is the gold standard to stage and monitor responses in Hodgkin lymphoma. This article reviewed the use of 2-[F-18]FDG-PET/CT in patients with Hodgkin lymphoma treated with ICI, focusing on image interpretation for response monitoring and detecting adverse events.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据